Daines, Colleagues Send Letter Urging Against Biden Admin’s Innovation-Stifling Drug Pricing Scheme
U.S. Senate — U.S. Senator Steve Daines joined his colleagues in sending a letter to the Biden Administration urging against the implementation of a drug-pricing scheme selected by the Department of Health and Human Services (HHS) that would stifle innovation and discourage research for new cures. “By bringing groundbreaking therapies to patients years before these products could otherwise reach the market, the FDA’s Accelerated Approval Program (AAP) has saved countless lives while upholding strong safeguards and standards. The Accelerating Clinical Evidence Model recently announced by the Biden Administration, unfortunately, risks undermining or even reversing this trend, triggering access gaps for seniors,